Bristol Myers Squibb Company (NYSE:BMY) is Four Tree Island Advisory LLC's 10th Largest Position

Four Tree Island Advisory LLC lifted its position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 28.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 66,556 shares of the biopharmaceutical company's stock after purchasing an additional 14,783 shares during the period. Bristol Myers Squibb accounts for 2.9% of Four Tree Island Advisory LLC's portfolio, making the stock its 10th largest holding. Four Tree Island Advisory LLC's holdings in Bristol Myers Squibb were worth $4,059,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of BMY. Brighton Jones LLC grew its stake in Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after buying an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG acquired a new position in Bristol Myers Squibb in the 4th quarter valued at about $13,094,000. Proficio Capital Partners LLC acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $240,000. Hillsdale Investment Management Inc. grew its position in shares of Bristol Myers Squibb by 3,400.0% during the 4th quarter. Hillsdale Investment Management Inc. now owns 14,000 shares of the biopharmaceutical company's stock worth $792,000 after purchasing an additional 13,600 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new position in shares of Bristol Myers Squibb during the 4th quarter worth approximately $817,000. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Bristol Myers Squibb

In related news, EVP Samit Hirawat bought 4,250 shares of the company's stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president owned 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.09% of the company's stock.

Bristol Myers Squibb Price Performance

BMY stock traded down $0.08 during midday trading on Thursday, reaching $48.91. The company had a trading volume of 3,910,074 shares, compared to its average volume of 13,339,816. The company has a debt-to-equity ratio of 2.65, a current ratio of 1.28 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1 year low of $44.00 and a 1 year high of $63.33. The company has a market capitalization of $99.53 billion, a P/E ratio of 18.33, a P/E/G ratio of 2.51 and a beta of 0.36. The firm has a 50-day moving average price of $47.57 and a 200-day moving average price of $52.76.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. Bristol Myers Squibb had a net margin of 11.38% and a return on equity of 87.62%. The company had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the prior year, the company earned ($4.40) EPS. The firm's revenue was down 5.6% on a year-over-year basis. On average, research analysts anticipate that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, August 1st. Stockholders of record on Thursday, July 3rd will be given a $0.62 dividend. The ex-dividend date is Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.07%. Bristol Myers Squibb's dividend payout ratio is 92.88%.

Analysts Set New Price Targets

A number of research analysts have issued reports on BMY shares. Morgan Stanley decreased their target price on shares of Bristol Myers Squibb from $36.00 to $34.00 and set an "underweight" rating on the stock in a research report on Thursday, July 10th. William Blair restated a "market perform" rating on shares of Bristol Myers Squibb in a research report on Friday, April 25th. UBS Group decreased their target price on shares of Bristol Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Argus raised shares of Bristol Myers Squibb to a "hold" rating in a report on Friday, April 25th. Finally, Wall Street Zen downgraded shares of Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $58.53.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.